Patent intelligence · DO
DO P2009000148
DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES
DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES
Patent details — DO P2009000148
- Jurisdiction
- DO
- Status
- granted
- Grant date
- Oct 15, 2010
- Expiration
- Oct 10, 2030
- Applicant
- BAYER SCHERING PHARMA AG [DE]
- CPC classes
- A61K/31416, A61P/100, A61P/1100, A61P/1102
Quick answer
DO P2009000148 (DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES) is held by BAYER SCHERING PHARMA AG [DE]. Status: granted. Granted Oct 15, 2010. Expires Oct 10, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER SCHERING PHARMA AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/31416, A61P/100, A61P/1100, A61P/1102, A61P/1106, A61P/1108
More from BAYER SCHERING PHARMA AG [DE]
Related pharmaceutical patents in our USPTO index.
-
IL 240179
Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject
granted -
ZA 201308176
THERAPEUTIC TREATMENT
granted -
SI 2158199
PIPERIDINE COMPOUNDS AND USES THEREOF
granted -
US 2010280048
Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
granted -
EP 2086964
BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN
granted -
EP 2079730
MGLUR5-MODULATOREN
granted -
EP 2064340
VERFAHREN ZUR BEWERTUNG VON PATIENTEN BEI DER BEHANDLUNG MIT AUF RET-REZEPTOR-TYROSINKINASE ABZIELENDEN ARZNEISTOFFEN
granted
Frequently asked questions
What is US patent P2009000148?
DO P2009000148 (DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES) is held by BAYER SCHERING PHARMA AG [DE]. Status: granted. Granted Oct 15, 2010. Expires Oct 10, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns DO P2009000148?
BAYER SCHERING PHARMA AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does DO P2009000148 expire?
Our index shows an expiration date of Oct 10, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.